DEVELOPMENTAL FUNDS Developmental funds were used in the last cycle for recruiting new investigators, supporting developmental projects, creating new shared resources, and helping fund several key staff investigators. Several outstanding investigators who received recruitment funds during the project period would not have come to Seattle without the extra support that was offered through the availability of CCSG New Investigator Awards, distributed to faculty from Fred Hutch (FH), University of Washington (UW), and Seattle Children?s (SC). The availability of CCSG Pilot Award funding provides investigators a very tangible benefit of Cancer Consortium membership and has stimulated new initiatives and collaborations that would otherwise not have occurred, particularly in transdisciplinary science, cancer health disparities, and catchment area health. Funds to catalyze new Shared Resource development have afforded Consortium members access to technologies and expertise that would otherwise not be sustainable in an individual laboratory or even on an institutional basis. Finally, developmental funds help support staff investigators focused on enhancing our community outreach and engagement efforts. During the last grant period, Developmental Funds supported the recruitment of 33 productive Consortium faculty members in areas of strategic growth and funded 45 Pilot Award projects. Together, these faculty members and pilot projects gave rise to a total of 439 publications and over $28M in new follow-on funding. In the last cycle, Developmental Funds were instrumental in the formation of the Hutch Data Commonwealth and supported two Special Populations Staff Investigators, both of whom continue to lead efforts to reduce disparities in underserved populations and one of whom has become the new Director of our Office of Community Outreach & Engagement. In this application, we are requesting funds to support future Pilot and New Investigator Awards, two new Special Populations Staff Investigators, and a Preclinical Models Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853668
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655

Showing the most recent 10 out of 1267 publications